Skip to content
OpenCapital
Get started

Apimeds Pharmaceuticals US, Inc. APUS Q3 2025 earnings

Reported November 12, 2025 · Before market open

Diluted EPS-$0.14

Next report

Date not yet announced

Versus estimates

Diluted EPS

Q1 2026-$2.26
Q3 2025-$0.14
Q2 2025-$0.26Q1 2025-$0.05Q4 2024-$0.02Q3 2024-$0.03

Ask the moment Apimeds Pharmaceuticals US, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Apimeds Pharmaceuticals US, Inc. report Q3 2025 earnings?
Apimeds Pharmaceuticals US, Inc. (APUS) reported Q3 2025 earnings on November 12, 2025 before market open.
What were Apimeds Pharmaceuticals US, Inc.'s Q3 2025 revenue and EPS?
Apimeds Pharmaceuticals US, Inc. reported diluted EPS of $-0.14 for Q3 2025.
How did Apimeds Pharmaceuticals US, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 434.4% from $-0.03.
Where can I find Apimeds Pharmaceuticals US, Inc.'s Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001213900-25-109280) directly on SEC EDGAR. The filing index links above go to sec.gov.